All In Biotech

NDA 208224 · Bayer Hlthcare

Kyleena

Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System

Last checked: Nov 20, 2026Latest source record: May 4, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Sep 16, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

354

70 Phase 3, 26 recruiting

FAERS reports

11,993

5,950 serious, 66 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2025.

Kyleena is indicated to prevent pregnancy for up to 5 years. Replace the system after 5 years if continued use is desired. Kyleena is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to 5 years. ( 1 )

Mechanism: The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Kyleena has not been conclusively demonstrated. Studies of Kyleena and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium .

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 16, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • KYLEENA · LEVONORGESTREL 19.5MG · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device expulsion2,145
  • device dislocation1,616
  • drug ineffective1,128
  • genital haemorrhage824
  • complication of device insertion674
  • abdominal pain lower662
  • pregnancy with contraceptive device487
  • procedural pain426
  • ectopic pregnancy with contraceptive device384
  • nausea337
  • vaginal haemorrhage330
  • headache295

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200439
200539
200637
200727
200822
200945
201064
201193
2012101
201345
201433
201572
2016119
2017395
2018934
20191,206
20201,548
20211,375
20221,391
20231,411
20241,168
20251,041
2026788

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kyleena (Levonorgestrel)

2024 spending

$43K

Beneficiaries

38

38 claims

Per beneficiary

$1,134

$1,134.12 per unit

View as table
YearSpending
2020$44,660
2021$37,600
2022$40,248
2023$48,910
2024$43,096

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,410 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.